14th International Conference on Complement Therapeutics

Program - Saturday, June 18

Important: The program online is copyrighted to each author and should not be copied and pasted!
  • Code of conduct

    Aegean Conferences is committed to making its meetings an inclusive space for sharing ideas and knowledge. The code of conduct can be found at:https://www.aegeanconferences.org/src/App/pages/view/AegeanCodeofConduct 

    Accommodations

    Accommodations for the conference are at the Sheraton Hotel. The Hotel is located in Ixia, Rhodes, 14.5 km from the airport.

    Arrival and Check-in 

    Attendees are expected to arrive/check-in after 3:00 PM local time. Registered participants arriving after 10:00 PM should make alternative dinner arrangements.  

    Conference Venue

    The Sheraton Conference Center is located at the hotel.  

    Handicapped Accessibility 

    The site is fully handicapped accessible. 

    Oral Presentations

    Speakers are asked to bring their USB flash drive to the reception desk at least 30 minutes prior to the session. The allocated time for all presentations, unless otherwise indicated, includes five minutes Q&A. 

    City Tour

    Buses for the city tour will depart from the hotel front lobby 3:00 PM. Badges are required for participation. 

    Breakfast

    Breakfast for registered participants and registered accompanying persons will be served at the Sheraton Hotel main restaurant during the hours scheduled in this program.

    Lunches/Informal Discussions

    Lunches for registered participants and registered accompanying persons will be served during the times indicated in this program at the main restaurant. Badges are required for admission.

    Dinners/Informal Discussions

    Three of the dinners/informal discussions will be served during the times indicated in the program. Vegetarian entrees are available only upon request in advance of the meeting. 

    Internet, Phone, & Computer 

    Wireless internet access is available throughout the conference center free of charge during meeting hours. 

    Certificate of Participation

    A Certificate of Participation will be distributed to a participant for those sessions that the participant has attended. A participant must attend an entire session to receive credit for that particular session. Late arrivals and early departures from a session will preclude a participant from receiving credit for that session.

    Meeting Room Policy

    Mask Recommendation

    Face masks are recommended indoors.

    No Photographs and Recording Devices 

    Participants are not allowed to photograph and/or record using cameras, mobile telephones and other recording devices during the slide and poster presentations. 

    Other Information

    Animals are not permitted on site. 

    Badges are required for admission to all events. 

    All Aegean Conferences events are non-smoking. 

     

    Aegean Conferences expects attendees to conform their conduct at these meetings to the policies and procedures of their employing institution or company. If we learn of improper conduct by an attendee, we will take appropriate action, including reporting such conduct to the attendee's employing institution or company and barring the attendee from participation in our meetings.

    The Aegean Conferences is committed to protecting the privacy of its visitors. Information that our meeting participants provide or that is derived from internal website tracking is not sold, rented or shared with any individual or organization.  You can let us know that you would prefer not to receive information by e-mail at any time, simply by sending an e-mail to unsubscribe@aegeanconferences.org. If you do so, we will not use your personal information for informing you on our future meetings and other services. 

Saturday, June 18

08:00 AM - 08:50 AM
Breakfast
08:50 AM - 09:00 AM
Welcome and Opening Remarks - John D. Lambris
Therapeutic complement modulation in severe COVID-19
Chairs: Carl Atkinson and Lisa Gralinski
09:00 AM - 09:20 AM
1
Targeting complement in COVID-19: where we stand and what lies ahead
Dimitrios C. Mastellos1, Panagiotis Skendros2, Markus Huber-Lang3, Bo Nilsson4, Antonio M. Risitano5, Konstantinos Ritis2, Despina Yancopoulou6, and John D. Lambris7
09:20 AM - 09:40 AM
2
Regulation of Inflammation by local complement in COVID-19
Ben Afzali
09:40 AM - 10:00 AM
3
Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules
Cecilia Garlanda
10:00 AM - 10:20 AM
4
Complement signaling mediates coronavirus-induced lung injury
Lisa E Gralinski, Ande West, Sarah R Leist, and Ralph S Baric
10:20 AM - 10:35 AM
5
The long pentraxin PTX3 modulates SARS-COV-2 immune response by interacting with Nucleocapsid protein
Matteo Stravalaci1, Niloufar Kavian-Tesslar1, Isabel Pagani2, Hang Zong1, Francesco Scavello1, Barbara Bottazzi1, Elisa Vicenzi2, Alberto Mantovani1,3,4, and Cecilia Garlanda1,3
10:35 AM - 10:50 AM
6
Genetic Determinants of Mannose-binding Lectin Activity Predispose to Thromboembolic Complications in Critical COVID-19
Michael Hultström2,8,9,10, Robert Frithiof2, Jonathan Grip3,11, Linnea Lindelöf1, Olav Rooijackers3,11, Sara Pigazzini4, Mari Niemi4, Mattia Cordioli4, Lindo Nkambule4, Tomislav Maricic5, Kristina Nilsson Ekdahl1,12, Bo Nilsson1, Miklós Lipcsey2,7, Hugo Zeberg5,6, and Oskar Eriksson1
10:50 AM - 11:30 AM
Coffee Break and Poster Viewing
Therapeutic development: novel complement inhibitors
Chairs: Cecilia Garlanda and Antonio Risitano
11:30 AM - 11:50 AM
7
Taking C3 inhibition to the next level: new insights and clinical opportunities
John D Lambris
11:50 AM - 12:10 PM
8
Discovering C3-targeting therapies for paroxysmal nocturnal hemoglobinuria: achievements and pitfalls
Antonio M Risitano1,3,4, Regis Peffault de Latour4,5, Luana Marano1, Camilla Frieri1,3,5, Despina Yancopoulou6, Dimitrios C Mastellos7, and John D Lambris
12:10 PM - 12:25 PM
9
Bifunctional complement inhibitor protects against autoantibody-mediated ischemia reperfusion injury in lung transplantation
Alexander McQuiston1, Changhai Li1, Zhenxiao Tu1, Kunal Patel2, Logan Langerude1, Stephen Tomlinson3, and Carl Atkinson1
12:25 PM - 12:40 PM
10
Design and in vitro Evaluation of Collectin-11 Antagonists for the Treatment of Ischemia-Reperfusion Injuries
Said Rabbani1, Rachel Hevey1, Martin Smiesko1, Daniel Ricklin1, and Roman Peter Jacob2
12:40 PM - 12:55 PM
11
Comparative efficacy of soluble CR1 variants in a mouse model of renal ischemia-reperfusion injury
Anjan K Bongoni3, Ingela B Vikstrom1, Jennifer L McRae3, Evelyn J Salvaris3, Nella Fisicaro3, Martin J Pearse1, Sandra Wymann2, Tony Rowe1, Adriana Bazmorelli1, Peter J Cowan3, and Matthew P Hardy1
12:55 PM - 01:10 PM
12
Development and testing of ‘super-functional’ Factor I based constructs for multiple disease modalities.
Thomas E Cox1, Helena Thomas Eke1, Jan K Jensen2, Thomas M Hallam1, Shyam R Iyer3, James McGuire3, and Kevin J Marchbank1
01:10 PM - 01:25 PM
13
Targeted colon delivery of pH-sensitive PMX205-loaded nanoparticles for the treatment of the inflammatory bowel disease.
Cedric S Cui1, Vinod Kumar1, Xaria X Li1, Ning Liu1, Richard J Clark1, Andrew K Whittaker2, Felicity Y Han2, John D Lee1, and Trent M Woodruff1
01:25 PM - 03:00 PM
Lunch and Informal Discussions
03:00 PM - 07:15 PM
Informal Discussions
07:15 PM - 10:30 PM
Dinner and Informal Discussions